Healthycell recently announced that it surpassed its $1.5 million Bridge Round, securing $1.62 million led by Keen Growth Capital with participation from the Balanced Breakfast Fund. The investment will enable Healthycell to accelerate customer acquisition, expand into brick-and-mortar retail, build out its consumer test kit offering, and complete IRB-approved clinical studies.
The Verona, New Jersey-based nutrition company uses patent-pending Microgel technology in their ingestible gel dietary supplement products which can be taken straight from the gel pack, mixed into drinks, or blended into smoothies.
Bioavailability
The technology ensures maximum absorption into the body by releasing extremely small, ultra-bioavailable, soluble nutrient particles in the digestive tract. Healthycell’s founder and CEO, Douglas Giampapa, told us that the new funding will help the company wrap up studies that demonstrate these absorption capabilities.
“We know that solubility is a prerequisite for bioavailability. Since our MICROGEL supplements are fully soluble, they are more bioavailable than most competing pill-form options. With our clinical study, we believe we will be able to put some hard numbers behind how much more bioavailable our solution is compared to the alternatives,” said Giampapa.
No gelling out
The investment comes amid rapid company growth, with Healthycell recently hitting several key milestones, including over 1,000 new customers per month, achieving industry-high retention rates, and completing its prototypes for direct-to-consumer test kits.